---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-171204"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:39:28.026128+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CHMP recommends EU marketing authorization for ARS Pharma's epinephrine nasal spray EURneffy

## Summary
- CHMP adopted positive opinion for EURneffy (2 mg epinephrine nasal spray) for emergency anaphylaxis treatment.
- Indicated for adults and children ≥30 kg; EC decision expected within 67 days of June 27, 2024.
- EURneffy is a needle-free alternative to injectable epinephrine, potentially expanding treatment access.
- Corporate presentation updated for investor meetings; no financial guidance changes reported.

## SEC filing metadata
- accession: 0001193125-24-171204
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312524171204/0001193125-24-171204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312524171204/d860381d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-171204
- JSON: https://secwatch.observer/filing/0001193125-24-171204.json
- Plain text: https://secwatch.observer/filing/0001193125-24-171204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.